Recent Advances in the Diagnosis and Treatment of Gastrointestinal Carcinoids

Advances in Surgery

Volumn 45, Issue 1, 2011, Pages 285-300

  Valentino, Joseph ^a   Evers, B Mark ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; DRUG DERIVATIVE; SOMATOSTATIN;

APPENDIX TUMOR; CARCINOID; CARCINOID SYNDROME; DUODENUM TUMOR; GASTROINTESTINAL TUMOR; HUMAN; LIVER TUMOR; METASTASIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REVIEW;

ANGIOGENESIS INHIBITORS; APPENDICEAL NEOPLASMS; CARCINOID TUMOR; DUODENAL NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; MALIGNANT CARCINOID SYNDROME; SOMATOSTATIN;

EID: 79961187846     PISSN: 00653411     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yasu.2011.03.014     Document Type: Review

References (86)

1. Lubarsch O. Uber den pimaeren krebs des ileum nebst Bemerkungen ueber das gleichzeitige Vorkommen von krebs und Tuberculos. Virchows Arch 1888, 111:280-317. [in German].
2. Oberndorfer S. Karzinoide tumoren des dunndarms. Frankf Z Pathol 1907, 1:425-429. [in German].
3. Modlin I.M., Lye K.D., Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003, 97(4):934-959.
4. Kulke M.H., Mayer R.J. Carcinoid tumors. N Engl J Med 1999, 340(11):858-868.
5. Modlin I.M., Oberg K., Chung D.C., et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008, 9(1):61-72.
6. Solcia E, Kloppel G, Sobin LH, et al. Histological typing of endocrine tumours. In: WHO international histological classification of tumours. 2nd edition. Springer (Berlin); 2000.
7. Modlin I.M., Kidd M., Latich I., et al. Current status of gastrointestinal carcinoids. Gastroenterology 2005, 128(6):1717-1751.
8. Woodside K.J., Townsend C.M., Mark Evers B. Current management of gastrointestinal carcinoid tumors. J Gastrointest Surg 2004, 8(6):742-756.
9. Scherubl H., Cadiot G., Jensen R.T., et al. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems?. Endoscopy 2010, 42(8):664-671.
10. Schindl M., Kaserer K., Niederle B. Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment. Arch Surg 2001, 136(1):49-54.
11. Bell H.K., Poston G.J., Vora J., et al. Cutaneous manifestations of the malignant carcinoid syndrome. Br J Dermatol 2005, 152(1):71-75.
12. Druce M., Rockall A., Grossman A.B. Fibrosis and carcinoid syndrome: from causation to future therapy. Nat Rev Endocrinol 2009, 5(5):276-283.
13. Bhattacharyya S., Davar J., Dreyfus G., et al. Carcinoid heart disease. Circulation 2007, 116(24):2860-2865.
14. Norheim I., Oberg K., Theodorsson-Norheim E., et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987, 206(2):115-125.
15. Bernheim A.M., Connolly H.M., Hobday T.J., et al. Carcinoid heart disease. Prog Cardiovasc Dis 2007, 49(6):439-451.
16. Borch K., Ahren B., Ahlman H., et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005, 242(1):64-73.
17. Boudreaux J.P., Putty B., Frey D.J., et al. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg 2005, 241(6):839-845. [discussion: 845-6].
18. Connor S.J., Hanna G.B., Frizelle F.A. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum 1998, 41(1):75-80.
19. Waisberg D.R., Fava A.S., Martins L.C., et al. Colonic carcinoid tumors: a clinicopathologic study of 23 patients from a single institution. Arq Gastroenterol 2009, 46(4):288-293.
20. Sauven P., Ridge J.A., Quan S.H., et al. Anorectal carcinoid tumors. Is aggressive surgery warranted?. Ann Surg 1990, 211(1):67-71.
21. Tormey W.P., FitzGerald R.J. The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. Postgrad Med J 1995, 71(839):542-545.
22. Nobels F.R., Kwekkeboom D.J., Coopmans W., et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997, 82(8):2622-2628.
23. Gladdy R.A., Strong V.E., Coit D., et al. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol 2009, 16(11):3154-3160.
24. Modlin I.M., Latich I., Zikusoka M., et al. Gastrointestinal carcinoids: the evolution of diagnostic strategies. J Clin Gastroenterol 2006, 40(7):572-582.
25. Horton K.M., Kamel I., Hofmann L., et al. Carcinoid tumors of the small bowel: a multitechnique imaging approach. AJR Am J Roentgenol 2004, 182(3):559-567.
26. Wong M., Kong A., Constantine S., et al. Radiopathological review of small bowel carcinoid tumours. J Med Imaging Radiat Oncol 2009, 53(1):1-12.
27. Reubi J.C., Waser B., Schaer J.C., et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001, 28(7):836-846.
28. Kwekkeboom D.J., Kam B.L., van Essen M., et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010, 17(1):R53-R73.
29. Virgolini I., Britton K., Buscombe J., et al. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002, 32(2):148-155.
30. Kwekkeboom D.J., Krenning E.P., Scheidhauer K., et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 2009, 90(2):184-189.
31. Krausz Y., Freedman N., Rubinstein R., et al. (68)Ga-DOTA-NOC PET/CT Imaging of Neuroendocrine Tumors: comparison with (111)In-DTPA-Octreotide (OctreoScan(R)). Mol Imaging Biol 2010, Available at:, Accessed March 16, 2011. http://www.springerlink.com/content/6t7074318377645j/.
32. Quigley A.M., Buscombe J.R., Shah T., et al. Intertumoural variability in functional imaging within patients suffering from neuroendocrine tumours. An observational, cross-sectional study. Neuroendocrinology 2005, 82(3-4):215-220.
33. Ruszniewski P., Delle Fave G., Cadiot G., et al. Well-differentiated gastric tumors/carcinomas. Neuroendocrinology 2006, 84(3):158-164.
34. Zyromski N.J., Kendrick M.L., Nagorney D.M., et al. Duodenal carcinoid tumors: how aggressive should we be?. J Gastrointest Surg 2001, 5(6):588-593.
35. Mullen J.T., Wang H., Yao J.C., et al. Carcinoid tumors of the duodenum. Surgery 2005, 138(6):971-977. [discussion: 977-8].
36. Makhlouf H.R., Burke A.P., Sobin L.H. Carcinoid tumors of the ampulla of Vater: a comparison with duodenal carcinoid tumors. Cancer 1999, 85(6):1241-1249.
37. Hatzitheoklitos E., Buchler M.W., Friess H., et al. Carcinoid of the ampulla of Vater. Clinical characteristics and morphologic features. Cancer 1994, 73(6):1580-1588.
38. Makridis C., Oberg K., Juhlin C., et al. Surgical treatment of mid-gut carcinoid tumors. World J Surg 1990, 14(3):377-383. [discussion: 384-5].
39. Stinner B., Kisker O., Zielke A., et al. Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum. World J Surg 1996, 20(2):183-188.
40. Moertel C.G., Weiland L.H., Nagorney D.M., et al. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 1987, 317(27):1699-1701.
41. Anderson J.R., Wilson B.G. Carcinoid tumours of the appendix. Br J Surg 1985, 72(7):545-546.
42. Syracuse D.C., Perzin K.H., Price J.B., et al. Carcinoid tumors of the appendix. Mesoappendiceal extension and nodal metastases. Ann Surg 1979, 190(1):58-63.
43. Landry C.S., Brock G., Scoggins C.R., et al. Proposed staging system for colon carcinoid tumors based on an analysis of 2,459 patients. J Am Coll Surg 2008, 207(6):874-881.
44. Konishi T., Watanabe T., Kishimoto J., et al. Prognosis and risk factors of metastasis in colorectal carcinoids: results of a nationwide registry over 15 years. Gut 2007, 56(6):863-868.
45. Onozato Y., Kakizaki S., Iizuka H., et al. Endoscopic treatment of rectal carcinoid tumors. Dis Colon Rectum 2010, 53(2):169-176.
46. Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. Cancer 2005, 103(8):1587-1595.
47. Yamaguchi N., Isomoto H., Nishiyama H., et al. Endoscopic submucosal dissection for rectal carcinoid tumors. Surg Endosc 2010, 24(3):504-508.
48. Jetmore A.B., Ray J.E., Gathright J.B., et al. Rectal carcinoids: the most frequent carcinoid tumor. Dis Colon Rectum 1992, 35(8):717-725.
49. Kwaan M.R., Goldberg J.E., Bleday R. Rectal carcinoid tumors: review of results after endoscopic and surgical therapy. Arch Surg 2008, 143(5):471-475.
50. Tsai B.M., Finne C.O., Nordenstam J.F., et al. Transanal endoscopic microsurgery resection of rectal tumors: outcomes and recommendations. Dis Colon Rectum 2010, 53(1):16-23.
51. Burke M., Shepherd N., Mann C.V. Carcinoid tumours of the rectum and anus. Br J Surg 1987, 74(5):358-361.
52. Koura A.N., Giacco G.G., Curley S.A., et al. Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival. Cancer 1997, 79(7):1294-1298.
53. Chamberlain R.S., Canes D., Brown K.T., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 2000, 190(4):432-445.
54. Mayo S.C., de Jong M.C., Pulitano C., et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 2010, 17:3129-3136.
55. Que F.G., Nagorney D.M., Batts K.P., et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995, 169(1):36-42. [discussion: 42-3].
56. Chambers A.J., Pasieka J.L., Dixon E., et al. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery 2008, 144(4):645-651. [discussion: 651-3].
57. Gupta S., Yao J.C., Ahrar K., et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 2003, 9(4):261-267.
58. Gupta S., Johnson M.M., Murthy R., et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005, 104(8):1590-1602.
59. Mazzaglia P.J., Berber E., Milas M., et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007, 142(1):10-19.
60. Kennedy A.S., Dezarn W.A., McNeillie P., et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008, 31(3):271-279.
61. Soreide O., Berstad T., Bakka A., et al. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 1992, 111(1):48-54.
62. Ohrvall U., Eriksson B., Juhlin C., et al. Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg 2000, 24(11):1402-1408.
63. Gulec S.A., Mountcastle T.S., Frey D., et al. Cytoreductive surgery in patients with advanced-stage carcinoid tumors. Am Surg 2002, 68(8):667-671. [discussion: 671-2].
64. Moller J.E., Pellikka P.A., Bernheim A.M., et al. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation 2005, 112(21):3320-3327.
65. Connolly H.M., Schaff H.V., Mullany C.J., et al. Carcinoid heart disease: impact of pulmonary valve replacement in right ventricular function and remodeling. Circulation 2002, 106(12 Suppl 1):I51-I56.
66. Nilsson O., Kolby L., Wangberg B., et al. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 1998, 77(4):632-637.
67. Reubi J.C., Kvols L.K., Waser B., et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990, 50(18):5969-5977.
68. Oberg K., Kvols L., Caplin M., et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004, 15(6):966-973.
69. Arnold R., Simon B., Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 2000, 62(Suppl 1):84-91.
70. Modlin I.M., Pavel M., Kidd M., et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010, 31(2):169-188.
71. Schmid H.A. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008, 286(1-2):69-74.
72. Rinke A., Muller H.H., Schade-Brittinger C., et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009, 27(28):4656-4663.
73. Valkema R., De Jong M., Bakker W.H., et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002, 32(2):110-122.
74. Anthony L.B., Woltering E.A., Espenan G.D., et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002, 32(2):123-132.
75. Van Essen M., Krenning E.P., De Jong M., et al. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007, 46(6):723-734.
76. Kwekkeboom D.J., de Herder W.W., Kam B.L., et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008, 26(13):2124-2130.
77. Kulke M.H. Clinical presentation and management of carcinoid tumors. Hematol Oncol Clin North Am 2007, 21(3):433-455. vii, viii.
78. Moertel C.G. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1983, 1(11):727-740.
79. Capurso G., Fazio N., Festa S., et al. Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives. Crit Rev Oncol Hematol 2009, 72(2):110-124.
80. Hobday T.J., Holen K., Donehower R., et al. A phase II trial of gefitinib in patients with progressive metastatic neuroendocrine tumors: a Phase II Consortium study. J Clin Oncol 2006, 24(18S):4043.
81. Terris B., Scoazec J.Y., Rubbia L., et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998, 32(2):133-138.
82. Capdevila J., Salazar R. Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors. Target Oncol 2009, 4(4):287-296.
83. Yao J.C., Phan A., Hoff P.M., et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008, 26(8):1316-1323.
84. Yao J.C., Phan A.T., Chang D.Z., et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008, 26(26):4311-4318.
85. National Comprehensive Cancer Network (NCCN) Guidelines for neuroendocrine tumors Available at:, Accessed April 18, 2011. http://www.nccn.org.
86. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005, 89(3):151-160.